[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA200901573A1 - Гетероарилзамещенные тиазолы - Google Patents

Гетероарилзамещенные тиазолы

Info

Publication number
EA200901573A1
EA200901573A1 EA200901573A EA200901573A EA200901573A1 EA 200901573 A1 EA200901573 A1 EA 200901573A1 EA 200901573 A EA200901573 A EA 200901573A EA 200901573 A EA200901573 A EA 200901573A EA 200901573 A1 EA200901573 A1 EA 200901573A1
Authority
EA
Eurasian Patent Office
Prior art keywords
relates
heteroaryl substituted
methods
substituted thiazoles
formula
Prior art date
Application number
EA200901573A
Other languages
English (en)
Inventor
Ксиангчжу Ванг
Суоминг Чжанг
Венкат Гадхачанда
Куиксиан Лиу
Шоуминг Ли
Джесс Куинн
Давэй Чэн
Майлинд Дешпенде
Авинаш Фадке
Original Assignee
Ачиллион Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ачиллион Фармасьютикалз, Инк. filed Critical Ачиллион Фармасьютикалз, Инк.
Publication of EA200901573A1 publication Critical patent/EA200901573A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Изобретение относится к гетероарилзамещенным тиазолам формулы I и II и их фармацевтически приемлемым солям. Переменные А и R-Rимеют значения, указанные в описании. Изобретение также относится к способам получения соединений формулы I и II и их солей. Настоящее изобретение также относится к фармацевтическим композициям, содержащим гетероарилзамещенные тиазолы, и способам применения гетероарилзамещенных тиазолов, включая способы применения соединений при лечении от вируса гепатита С.
EA200901573A 2007-05-22 2008-05-22 Гетероарилзамещенные тиазолы EA200901573A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93942407P 2007-05-22 2007-05-22
PCT/US2008/006676 WO2008147557A2 (en) 2007-05-22 2008-05-22 Heteroaryl substituted thiazoles and their use as antiviral agents

Publications (1)

Publication Number Publication Date
EA200901573A1 true EA200901573A1 (ru) 2010-04-30

Family

ID=39739656

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200901573A EA200901573A1 (ru) 2007-05-22 2008-05-22 Гетероарилзамещенные тиазолы

Country Status (12)

Country Link
US (1) US8183263B2 (ru)
EP (1) EP2164846A2 (ru)
JP (1) JP2010528019A (ru)
KR (1) KR20100020484A (ru)
CN (1) CN101801964A (ru)
AU (1) AU2008257158A1 (ru)
BR (1) BRPI0811939A2 (ru)
CA (1) CA2687817A1 (ru)
EA (1) EA200901573A1 (ru)
IL (1) IL202139A0 (ru)
MX (1) MX2009012613A (ru)
WO (1) WO2008147557A2 (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007013955A (es) * 2005-05-09 2008-02-05 Achillion Pharmaceuticals Inc Compuestos de tiazol y metodos de uso.
JP2009529059A (ja) * 2006-03-08 2009-08-13 アキリオン ファーマシューティカルズ，インコーポレーテッド 抗ｃ型肝炎ウイルス活性を有する置換アミノチアゾール誘導体
US20110105436A1 (en) * 2008-03-10 2011-05-05 Auckland Uniservices Limited Heteroaryl compounds, compositions, and methods of use in cancer treatment
US8106209B2 (en) * 2008-06-06 2012-01-31 Achillion Pharmaceuticals, Inc. Substituted aminothiazole prodrugs of compounds with anti-HCV activity
CN102131806A (zh) * 2008-06-20 2011-07-20 百时美施贵宝公司 用作激酶抑制剂的三唑并吡啶化合物
MX357867B (es) 2011-05-27 2018-07-19 Achillion Pharmaceuticals Inc Alifanos, ciclofanos, heterafanos, heterofanos, hetero-heterafanos y metalocenos sustituidos utiles para tratar infecciones por el vhc.
US9278089B2 (en) 2011-10-26 2016-03-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of treating HCV infection with a small molecule CHK2 inhibitor
TWI475016B (zh) * 2012-05-11 2015-03-01 Beijing Beta Pharma Inc 一組提高激酶活性的化合物及其應用
KR20150112035A (ko) * 2013-03-05 2015-10-06 에프. 호프만-라 로슈 아게 Hcv-항바이러스제로서의 n-헤테로아릴 치환된 아닐린 유도체
CN107635981B (zh) * 2015-02-17 2020-08-04 中国科学院广州生物医药与健康研究院 用于诱导白色脂肪组织褐变的化合物和方法
CA2977401A1 (en) 2015-02-27 2016-09-01 The Regents Of The University Of California Small molecules that enable cartilage rejuvenation
CN106467501B (zh) * 2015-08-18 2018-10-26 中国医学科学院医药生物技术研究所 新型抗病毒化合物
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3467666A (en) 1966-11-07 1969-09-16 Geigy Chem Corp 2-substituted aminothiazoles
BE795907A (fr) 1972-02-25 1973-06-18 Luso Farmaco Inst 2-amino-4-arylthiazoles 5-substitues et leur preparation
DE3406329A1 (de) 1984-02-22 1985-08-22 Merck Patent Gmbh, 6100 Darmstadt Pyridone
US5856347A (en) 1994-11-29 1999-01-05 Hisamitsu Pharmaceutical Co., Inc. Antibacterial preparation or bactericide comprising 2-aminothiazole derivative and/or salt thereof
MY128323A (en) 1996-09-30 2007-01-31 Otsuka Pharma Co Ltd Thiazole derivatives for inhibition of cytokine production and of cell adhesion
WO2000006575A2 (en) 1998-07-28 2000-02-10 Smithkline Beecham Plc Azabicyclic compounds
AU762245B2 (en) 1998-09-18 2003-06-19 Vertex Pharmaceuticals Incorporated Inhibitors of p38
WO2000033837A2 (en) 1998-12-07 2000-06-15 Smithkline Beecham Corporation Myt1 kinase inhibitors
WO2001021160A2 (en) 1999-09-23 2001-03-29 Axxima Pharmaceuticals Aktiengesellschaft Carboxymide and aniline derivatives as selective inhibitors of pathogens
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
ES2317889T3 (es) 2000-03-01 2009-05-01 Janssen Pharmaceutica Nv Derivados de tiazolilo 2,4-disustituido.
WO2001074793A2 (en) 2000-04-03 2001-10-11 3-Dimensional Pharmaceuticals, Inc. Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1
WO2002051410A2 (en) 2000-12-22 2002-07-04 Akzo Nobel N.V. Phenylthiazole and thiazoline derivatives and their use as antiparasitics
WO2002051442A1 (fr) 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Co-prescriptions
WO2002059099A1 (fr) 2001-01-26 2002-08-01 Shionogi & Co., Ltd. Composes cycliques presentant un agonisme envers le recepteur de thrombopoietine
IL160329A0 (en) 2001-08-13 2004-07-25 Janssen Pharmaceutica Nv 2-amino-4,5-trisubstituted thiazolyl derivatives
EP1432698A2 (en) 2001-09-26 2004-06-30 Bayer Pharmaceuticals Corporation Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
US20040267017A1 (en) 2001-09-26 2004-12-30 Bierer Donald E 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors
JP2005509606A (ja) 2001-10-03 2005-04-14 ファルマシア・コーポレーション 凝血カスケードを選択的に阻害するのに有用な置換された多環式化合物のプロドラッグ
EP1452530A4 (en) 2001-12-03 2005-11-30 Japan Tobacco Inc AZOL CONNECTION AND THEIR MEDICAL USE
DE60221627D1 (de) 2001-12-21 2007-09-20 Virochem Pharma Inc Thiazolderivate und ihre Verwendung zur Behandlung oder Vorbeugung von Infektionen durch Flaviviren
CA2474322A1 (en) 2002-01-25 2003-07-31 Kylix Pharmaceuticals B.V. 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
WO2003066215A1 (fr) 2002-02-06 2003-08-14 Japan Energy Corporation Procede de preparation de catalyseur d'hydrogenation de purification
EP1525200B1 (en) 2002-08-02 2007-10-10 AB Science 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors
DK1599468T3 (da) 2003-01-14 2008-02-04 Arena Pharm Inc 1,2,3-trisubstituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser forbundet dermed såsom diabetes og hyperglykæmi
US7115746B2 (en) 2003-02-10 2006-10-03 Vertex Pharmaceuticals Incorporated Processes for the facile synthesis of diaryl amines and analogues thereof
EP1594847A2 (en) 2003-02-12 2005-11-16 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
JP2006519220A (ja) 2003-02-27 2006-08-24 アブ サイエンス 異なる型の肥満細胞症に適合可能なテイラーメイド治療方法
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
JP2006523671A (ja) 2003-04-15 2006-10-19 ファイザー・インク ＰＰＡＲ調節剤としてのα置換カルボン酸
US20070191267A1 (en) 2003-04-28 2007-08-16 Ab Science Use of tyrosine kinase inhibitors for treating cerebral ischemia
WO2004098612A2 (en) 2003-05-07 2004-11-18 Ab Science Calcitriol analogs of uses thereof
EP1628666B1 (en) * 2003-05-14 2015-09-23 NeuroGenetic Pharmaceuticals, Inc. Compouds and uses thereof in modulating amyloid beta
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
JP2007502809A (ja) 2003-08-15 2007-02-15 アブ サイエンス ＩＩ型糖尿病を治療するためのｃ−ｋｉｔ阻害剤の使用方法
WO2005051318A2 (en) 2003-11-24 2005-06-09 Viropharma Incorporated Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
KR100773650B1 (ko) 2003-12-08 2007-11-05 에프. 호프만-라 로슈 아게 신규한 싸이아졸 유도체
NZ548884A (en) 2004-01-30 2010-06-25 Ab Science 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors
WO2005077368A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
TW200538433A (en) 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
WO2005099673A1 (en) 2004-04-13 2005-10-27 Icagen, Inc. Polycylic thiazoles as potassium ion channel modulators
EP1755592A1 (en) 2004-04-20 2007-02-28 AB Science Use of c-kit inhibitors for treating inflammatory muscle disorders including myositis and muscular dystrophy
WO2005102318A1 (en) 2004-04-20 2005-11-03 Ab Science Use of c-kit inhibitors for treating hiv related diseases
CA2564570A1 (en) 2004-04-23 2005-11-03 Ab Science Use of c-kit inhibitors for treating plasmodium related diseases
WO2005102326A2 (en) 2004-04-23 2005-11-03 Ab Science Use of c-kit inhibitors for treating renal diseases
US20070225293A1 (en) 2004-04-23 2007-09-27 Ab Science Use of C-Kit Inhibitors for Treating Fibrosis
EP1746990A1 (en) 2004-05-18 2007-01-31 AB Science Use of mast cells inhibitors for treating patients exposed to chemical or biological weapons
WO2005115385A1 (en) 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating acne
WO2005115304A2 (en) 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating fibrodysplasia
US20070275968A1 (en) 2004-09-07 2007-11-29 Hitoshi Kurata Substituted Biphenyl Derivative
WO2006033005A2 (en) 2004-09-23 2006-03-30 Pfizer Products Inc. Thrombopoietin receptor agonists
EP2527337A1 (en) 2005-04-14 2012-11-28 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
MX2007013955A (es) * 2005-05-09 2008-02-05 Achillion Pharmaceuticals Inc Compuestos de tiazol y metodos de uso.
EP1885704B1 (en) 2005-05-11 2011-09-28 Abbott Laboratories Antagonists of the vanilloid receptor subtype 1 (vr1) and uses thereof
EP1904065A2 (en) 2005-07-14 2008-04-02 AB Science Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma
US20070135368A1 (en) 2005-12-09 2007-06-14 Knapp Pamela E Cell-to-cell transmission of siRNA induced gene silencing in mammalian cells
UY30117A1 (es) 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compuesto amina trisustituido
JP5268652B2 (ja) 2006-02-01 2013-08-21 メルク・シャープ・アンド・ドーム・コーポレーション カリウムチャンネルインヒビター
US8735595B2 (en) 2006-02-15 2014-05-27 Abbvie Inc. Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
JP2009529059A (ja) * 2006-03-08 2009-08-13 アキリオン ファーマシューティカルズ，インコーポレーテッド 抗ｃ型肝炎ウイルス活性を有する置換アミノチアゾール誘導体
WO2008033932A2 (en) 2006-09-13 2008-03-20 The Institutes For Pharmaceutical Discovery, Llc Biarylthiazole carboxylic acid derivatives as protein tyrosine phosphatase-ib inhibitors

Also Published As

Publication number Publication date
WO2008147557A2 (en) 2008-12-04
MX2009012613A (es) 2010-04-21
US20090041720A1 (en) 2009-02-12
WO2008147557A3 (en) 2009-03-05
EP2164846A2 (en) 2010-03-24
IL202139A0 (en) 2010-06-16
KR20100020484A (ko) 2010-02-22
JP2010528019A (ja) 2010-08-19
BRPI0811939A2 (pt) 2014-11-25
CN101801964A (zh) 2010-08-11
CA2687817A1 (en) 2008-12-04
AU2008257158A1 (en) 2008-12-04
US8183263B2 (en) 2012-05-22

Similar Documents

Publication Publication Date Title
EA200901573A1 (ru) Гетероарилзамещенные тиазолы
EA201290260A1 (ru) Бензимидазол-имидазольные производные
CY1116885T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλομεθυλιου
EA201491329A1 (ru) 4,4-дизамещенные 1,4-дигидропиримидины и их применение в качестве лекарственных препаратов для лечения гепатита b
EA200900066A1 (ru) Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-c-(3-((фенил)метил)фенил) -d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета
EA201270560A1 (ru) Спиропиперидиновые соединения и их фармацевтическое применение для лечения диабета
MX2010008699A (es) Derivados heterociclicos como inhibidores de virus de la hepatitis c.
CY1117576T1 (el) Δινουκλεοτιδικα προφαρμακα
EA201290089A1 (ru) Химические соединения
EA201491179A1 (ru) 2',4'-дифтор-2'-метил замещенные нуклеозидные производные в качестве ингибиторов репликации рнк вируса гепатита с
EA201491824A1 (ru) Производные бензамида для ингибирования активности abl1, abl2 и bcr-abl1
EA201001508A1 (ru) Мостиковые гетероциклические соединения в качестве ингибиторов интегразы вич
EA200901241A1 (ru) Соединения для лечения гепатита с
EA201100390A1 (ru) Соединения для лечения гепатита с
EA201290416A1 (ru) Новые спиропиперидиновые соединения
CY1112999T1 (el) Αναστολεις ιου ηπατιτιδας c
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
EA201100482A1 (ru) Кристаллические формы 2-тиазолил-4-хинолинилоксипроизводного, активного ингибитора hcv
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
EA201500266A1 (ru) Ингибиторы репликации вирусов гриппа
EA201200669A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
NZ595186A (en) Di-pyrazolidinyl-biphenylyl compounds for treating hepatitis C virus (HCV) infection
EA201591328A1 (ru) Замещенные гетероциклом тетрациклические соединения и способы их применения для лечения вирусных заболеваний
EA201200318A1 (ru) Гетероциклические оксимы